Sarah B. Noonberg
CIK 1706301 · View on SEC EDGAR ↗
Insider
First SEC filing: Feb. 8, 2024 · Latest: Feb. 8, 2024
On this page
- Insider at Companies where this person is a reporting insider.
- Insider transactions Every share this person bought or sold, from Form 4 filings.
- Derivatives Options and other derivative holdings reported by this person.
- Initial holdings The stakes this person held when they first started reporting.
- Compensation Executive pay disclosed in company proxy statements.
Insider at
Insider transactions
0 buys (P)
0 sells (S)
Net:
$0
+ 25 non-open-market transactions below
last 12 months, based on the transactions shown below
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
25 other filings hidden
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| June 6, 2025 | MGX | S | 5,239 | $1.75 | $9,168 | 109,135 Direct | -4.58% | Disposed | -29.7% (price as of 2026-08-21) |
| Feb. 11, 2021 | PTGX | S 10b5-1 | 3,700 | $25.09 | $92,833 | 0 Direct | -100.00% | Disposed | 505.2% (price as of 2026-08-21) |
| Feb. 10, 2021 | PTGX | S 10b5-1 | 400 | $26.04 | $10,416 | 0 Direct | -100.00% | Disposed | 483.1% (price as of 2026-08-21) |
| Feb. 10, 2021 | PTGX | S 10b5-1 | 4,300 | $25.42 | $109,306 | 400 Direct | -91.49% | Disposed | 497.4% (price as of 2026-08-21) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| June 12, 2025 | NGNE | Non-Qualified Stock Option (right to buy) | Common Stock (12,050) | $20.40 | June 12, 2035 | 12,050 | Acquired |
| April 1, 2025 | MGX | Stock Option (Right to Buy) | Common Stock (84,000) | $1.32 | March 31, 2035 | 84,000 | Acquired |
| June 14, 2024 | NGNE | Stock Option (Right to Buy) | Common Stock (7,700) | $42.59 | June 14, 2034 | 7,700 | Acquired |
| April 1, 2024 | MGX | Stock Option (Right to Buy) | Common Stock (242,875) | $10.82 | March 31, 2034 | 242,875 | Acquired |
| Jan. 16, 2024 | NGNE | Stock Option (Right to Buy) | Common Stock (15,400) | $32.30 | Jan. 16, 2034 | 15,400 | Acquired |
| June 8, 2023 | NGNE | Stock Option (Right to Buy) | Common Stock (25,000) | $0.79 | June 7, 2033 | 25,000 | Acquired |
| Jan. 16, 2023 | PTGX | Stock Option (right to buy) | Common Stock (30,000) | $12.17 | Jan. 15, 2033 | 30,000 | Acquired |
| May 26, 2022 | PTGX | Stock Option (right to buy) | Common Stock (20,000) | $8.31 | May 26, 2032 | 20,000 | Acquired |
| May 12, 2022 | NGNE | Stock Option (Right to Buy) | Common Stock (25,000) | $1.07 | May 11, 2032 | 25,000 | Acquired |
| May 27, 2021 | PTGX | Stock Option (right to buy) | Common Stock (18,000) | $35.23 | May 26, 2031 | 18,000 | Acquired |
| May 11, 2021 | NGNE | Stock Option (Right to Buy) | Common Stock (25,000) | $11.40 | May 10, 2031 | 25,000 | Acquired |
| Feb. 11, 2021 | PTGX | Stock Option (right to buy) | Common Stock (3,700) | $6.98 | May 28, 2028 | 3,700 | Disposed |
| Feb. 10, 2021 | PTGX | Stock Option (right to buy) | Common Stock (4,700) | $6.98 | May 28, 2028 | 4,700 | Disposed |
| May 28, 2020 | PTGX | Stock Option (right to buy) | Common Stock (15,000) | $16.54 | May 27, 2030 | 15,000 | Acquired |
| May 5, 2020 | NGNE | Stock Option (Right to Buy) | Common Stock (25,000) | $12.84 | May 5, 2030 | 25,000 | Acquired |
| Oct. 10, 2019 | NGNE | Stock Option (right to buy) | Common Stock (22,000) | $2.82 | Oct. 9, 2029 | 22,000 | Acquired |
| June 7, 2019 | PTGX | Stock Option (right to buy) | Common Stock (12,000) | $11.80 | June 6, 2029 | 12,000 | Acquired |
| May 29, 2018 | PTGX | Stock Option (right to buy) | Common Stock (12,000) | $6.98 | May 28, 2028 | 12,000 | Acquired |
| Dec. 15, 2017 | PTGX | Stock Option (right to buy) | Common Stock (24,000) | — | Dec. 14, 2027 | 24,000 | Acquired |
| Dec. 15, 2017 | PTGX | Stock Option (right to buy) | Common Stock (24,000) | $17.57 | Dec. 14, 2027 | 24,000 | Acquired |
| May 16, 2017 | PRTA | Stock Option (right to buy) | Ordinary Shares (100,000) | $56.37 | May 16, 2027 | 100,000 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 1 holding
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| Feb. 8, 2024 | MGX | Common Stock | 42,611 | Direct |
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
PRTA
M.D., Ph.D.(5)Former Chief Medical Officer| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2017 | $310,000 | $100,000 | — | — | $124,000 | — | $8,100 | $4,182,170 |
| 2016 | — | — | — | — | — | — | — | — |
| 2015 | — | — | — | — | — | — | — | — |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.